Cardiology
At the Heart of Innovation !
EARLY DETECTION OF THE CARDIAC EFFECTS OF ANTICANCER DRUGS
Over the past 20 years, the prognosis for cancer patients has steadily improved. However, the potential long-term complications of certain treatments, particularly those affecting the heart, are now a major concern. Indeed, although rare, cardiac complications of cancer treatments are nowadays managed late, when the heart muscle becomes less efficient. The aim of the laboratory’s work is to develop imaging tracers (molecules injected into patients and then detected by non-invasive imaging) that can detect the cardiac impact of treatments before they affect the heart pump. To date, we have identified 2 candidate imaging tracers, one of which is particularly precocious in that it can detect future cardiac toxicity as early as the 1st treatment administrations. However, it still needs to be improved before it can be considered for the first clinical trials.
Associated publications: